Ultromics
Ultromics develops FDA-cleared EchoGo software that applies AI to routine echocardiograms to detect heart failure with preserved ejection fraction and cardiac amyloidosis.
About
Ultromics builds AI software for cardiac diagnosis, spun out of the University of Oxford in 2017. Its EchoGo Heart Failure and EchoGo Amyloidosis products analyze standard echocardiogram studies to help clinicians identify HFpEF and cardiac amyloidosis, and they plug into existing hospital echo workflows. Both products have FDA 510(k) clearance, and the company points to a CPT billing code for reimbursement. Ultromics reports clinical evidence published in peer-reviewed journals and works with U.S. health systems including Mayo Clinic, City of Hope and University Hospitals, as well as the UK's NHS supply chain framework.
- Organization type
- ai company
- Headquarters region
- United Kingdom
- Founded
- 2017
- Listings in the graph
- 0
- Last updated
- 6 October 2026
- Published
- 6 October 2026
Data sources & provenance
Where this information came from, how it was checked and when it was last looked at. “Last updated” records a change to the record — it does not mean the record was verified.
- Data quality
- Data quality: Editorially Reviewed
- Primary source
- ultromics.com
- Sources cited
- 2
- Last reviewed
- 6 October 2026
- Last updated
- 6 October 2026
Spotted something out of date?
Anyone can suggest a correction — you don't need an account. An editor checks every suggestion against the sources before the record changes.
Products & technologies
No published products from this organization yet.
Services
No published services from this organization yet.
News & insights from this region
No related coverage published yet.
Events in this region
No related events published yet.
Learning resources
No learning resources from this provider yet.
Is this your organization?
Claim this profile to keep the description, products and services accurate, or add an organization that is missing from the graph.